Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children

Simple item page
dc.contributor.authorMadhi S.A.
dc.contributor.authorNachman S.
dc.contributor.authorViolari A.
dc.contributor.authorKim S.
dc.contributor.authorCotton M.F.
dc.contributor.authorBobat R.
dc.contributor.authorJean-Philippe P.
dc.contributor.authorMcSherry G.
dc.contributor.authorMitchell C.
dc.date.accessioned2011-10-13T16:59:17Z
dc.date.available2011-10-13T16:59:17Z
dc.date.issued2011
dc.description.abstractBACKGROUND: The dual epidemic of human immunodeficiency virus (HIV) and tuberculosis is a major cause of sickness and death in sub-Saharan Africa. We conducted a double-blind, randomized, placebo-controlled trial of preexposure isoniazid prophylaxis against tuberculosis in HIV-infected children and uninfected children exposed to HIV during the perinatal period. METHODS: We randomly assigned 548 HIV-infected and 804 HIV-uninfected infants (91 to 120 days of age) to isoniazid (10 to 20 mg per kilogram of body weight per day) or matching placebo for 96 weeks. All patients received bacille Calmette-Guérin (BCG) vaccination against tuberculosis within 30 days after birth. HIV-infected children had access to antiretroviral therapy. The primary outcome measures were tuberculosis disease and death in HIV-infected children and latent tuberculosis infection, tuberculosis disease, and death in HIV-uninfected children within 96 to 108 weeks after randomization. RESULTS: Antiretroviral therapy was initiated in 98.9% of HIV-infected children during the study. Among HIV-infected children, protocol-defined tuberculosis or death occurred in 52 children (19.0%) in the isoniazid group and 53 (19.3%) in the placebo group (P = 0.93). Among HIV-uninfected children, there was no significant difference in the combined incidence of tuberculosis infection, tuberculosis disease, or death between the isoniazid group (39 children, 10%) and the placebo group (45 children, 11%; P = 0.44). The rate of tuberculosis was 121 cases per 1000 child-years (95% confidence interval [CI], 95 to 153) among HIV-infected children as compared with 41 per 1000 child-years (95% CI, 31 to 52) among HIV-uninfected children. There were no significant differences in clinical or severe laboratory toxic effects between treatment groups. CONCLUSIONS: Primary isoniazid prophylaxis did not improve tuberculosis-disease- free survival among HIV-infected children or tuberculosis-infection-free survival among HIV-uninfected children immunized with BCG vaccine. Despite access to antiretroviral therapy, the burden of tuberculosis remained high among HIV-infected children. (Funded by the National Institutes of Health and Secure the Future; ClinicalTrials.gov number, NCT00080119.) Copyright © 2011 Massachusetts Medical Society.
dc.description.versionArticle
dc.identifier.citationNew England Journal of Medicine
dc.identifier.citation365
dc.identifier.citation1
dc.identifier.citationhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79960100289&partnerID=40&md5=bbb243842ec5f6030877cdd5d8e16d82
dc.identifier.issn284793
dc.identifier.other10.1056/NEJMoa1011214
dc.identifier.urihttp://hdl.handle.net/10019.1/17049
dc.titlePrimary isoniazid prophylaxis against tuberculosis in HIV-exposed children
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications